CEO fires back at short-seller Citron on live TV: ‘Mr. Left is dead wrong’
Berkeley Lovelace Jr.
CNBC, 15 May 2017
Exact Sciences Chairman and CEO Kevin Conroy fired back at a bearish assessment made by Citron Research’s Andrew Left, who predicted a long-term drop in the cancer testing company’s stock to a near-zero single digit.
Citron said in a report on Monday that Exact Sciences’ Cologuard cancer test, an at home screening for colon cancer, is “inferior” and shouldn’t be pitching it as an alternative to a colonoscopy.
Read full article.
Comment: Andrew Left’s Citron appears to be a front for naked short sellers.
Citron Research “Exposes” Exact Sciences – Short Term Target $20
ValueWalk.com, 15 May 2017
Citron Research exposes Exact Sciences and PROVES beyond ANY doubt why this stock will soon be cut in half – so says a new reprot from Citron Research – Citron founder Andrew Left battled the CEO of Exact on CNBC on that topic for CNBC pro sub subscribers you can find that video here
Comment: Knocked stock down from $30 to $22. They needed to cover, stock then went to $125.